Boehringer Ingelheim and GoodRx are launching a patient affordability initiative to provide citrate-free Adalimumab-adbm, Boehringer’s biosimilar to Humira (adalimumab), at a low cash price available ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback